Characteristics of patients undergoing A-BMT
Patient no. . | FAB classification . | Sex . | Age at diagnosis, y . | Cytogenetic data . | WBC count at diagnosis, × 109/L . | First-line chemotherapy (complete remission after induction therapy: yes/no) . | Conditioning regimen . | Interval between diagnosis and A-BMT, mo . | No. of cells infused, × 108/kg . | Outcome (+mo elapsed from A-BMT) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | M2 | F | 2.4 | t(6;9) | 66 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 1.5 | A&W (+64) |
| 7 | M5a | M | 14 | Normal karyotype | 4.6 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 1.0 | A&W (+47) |
| 8 | M5a | M | 9 | (45,XY)-7 | 2 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.4 | A&W (+42) |
| 9 | M6 | F | 7.5 | Normal karyotype | 70 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.0 | Relapsed (+5); died due to disease progression |
| 10 | M4 | M | 15.2 | Normal karyotype | 192 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 5 | 1.3 | Relapsed (+6); died after unrelated donor BMT |
| 11 | M5a | M | 1.2 | Normal karyotype | 132 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | BAVC | 4 | 3.7 | Relapsed (+9); died after haploidentical BMT |
| 12 | M4 | M | 1.7 | Normal karyotype | 78 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | BU/CY/L-PAM | 5 | 4.4 | A&W (+31) |
| 13 | M1 | M | 14 | Normal karyotype | 23 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 1.2 | A&W (+30) |
| 14 | M2 | F | 7 | Normal karyotype | 2.7 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.5 | Relapsed (+9); A&W after unrelated donor BMT |
| 15 | M5a | M | 16 | t(9;11) | 99 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.3 | A&W (+21) |
| 16 | M5a | F | 1 | Normal karyotype | 38 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 7 | 4.5 | A&W (+68) |
Patient no. . | FAB classification . | Sex . | Age at diagnosis, y . | Cytogenetic data . | WBC count at diagnosis, × 109/L . | First-line chemotherapy (complete remission after induction therapy: yes/no) . | Conditioning regimen . | Interval between diagnosis and A-BMT, mo . | No. of cells infused, × 108/kg . | Outcome (+mo elapsed from A-BMT) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | M2 | F | 2.4 | t(6;9) | 66 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 1.5 | A&W (+64) |
| 7 | M5a | M | 14 | Normal karyotype | 4.6 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 1.0 | A&W (+47) |
| 8 | M5a | M | 9 | (45,XY)-7 | 2 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.4 | A&W (+42) |
| 9 | M6 | F | 7.5 | Normal karyotype | 70 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.0 | Relapsed (+5); died due to disease progression |
| 10 | M4 | M | 15.2 | Normal karyotype | 192 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 5 | 1.3 | Relapsed (+6); died after unrelated donor BMT |
| 11 | M5a | M | 1.2 | Normal karyotype | 132 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | BAVC | 4 | 3.7 | Relapsed (+9); died after haploidentical BMT |
| 12 | M4 | M | 1.7 | Normal karyotype | 78 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | BU/CY/L-PAM | 5 | 4.4 | A&W (+31) |
| 13 | M1 | M | 14 | Normal karyotype | 23 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 1.2 | A&W (+30) |
| 14 | M2 | F | 7 | Normal karyotype | 2.7 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.5 | Relapsed (+9); A&W after unrelated donor BMT |
| 15 | M5a | M | 16 | t(9;11) | 99 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 4 | 2.3 | A&W (+21) |
| 16 | M5a | F | 1 | Normal karyotype | 38 | ICE (3 + 5 + 10) × 2; AVE; HAM (yes) | TBI + L-PAM | 7 | 4.5 | A&W (+68) |
ICE indicates idarubicin 12 mg/m2/d 60-minute infusion on days 1, 3, 5; etoposide 100 mg/m2/d 1-hour IV infusion on days 1-5; cytarabine 25 mg/m2/d IV push on day 1 followed by 100 mg/m2/d continuous IV infusion on days 1-10; AVE, high-dose cytarabine 3 g/m2 3-hour infusion every 12 hours for 3 days and etoposide 125 mg/m2/d 1-hour IV infusion for 4 days; HAM, high-dose cytarabine 3 g/m2 3-hour infusion every 12 hours for 3 days and mitoxantrone 10 mg/m2 60-minute infusion for 2 days; TBI, total body irradiation (990-1200 cGy); L-PAM, melphalan (140 mg/m2); BU, busulfan (16 mg/kg); CY, cyclophosphamide (120 mg/kg); BAVC, BCNU (800 mg/m2), amsacrine (450 mg/m2), etoposide (450 mg/m2), and cytarabine (900 mg/m2).